Searched for
ALOK DALAL
PB Fintech shares in focus after founders sell stake worth Rs 665 crore in Policybazaar parentPB Fintech founders sold shares worth Rs 665 crore. Yashish Dahiya and Alok Bansal offloaded stock on Friday. Major investors like Goldman ...- Crude at $125, FIIs selling $20 billion, and yet Alchemy Capital's Alok Agarwal says India is a buyIndian equities present a compelling opportunity for patient investors. Recent underperformance has already factored in negative news. Alok...
- Digital lenders wary of small biz; Mythos’ biggest security riskHappy Tuesday! Digital lending firms are turning cautious on term loan exposure to small businesses. This and more in today’s ETtech Mornin...
- Trump tariffs hit patented drugs: Jefferies, Nomura explain impact on pharma stocksThe US has slapped up to 100% tariffs on patented drugs, sparing generics and biosimilars but exposing India’s speciality pharma players. S...
- Kuku forays into film production with first Hindi theatrical releaseKuku FM and Kuku TV are venturing into movie theaters. Their first Hindi film, Indian Institute of Zombies, is a campus comedy. It blends h...
- Two Desktops and a Printer: Ixigo boss Aloke Bajpai shares 'How It All Started' pic on stock listingIxigo, led by co-founder Aloke Bajpai, made a strong debut on Dalal Street with its shares closing 78% higher than the issue price, valuing...
- IPL-flavoured portfolio: How Alok Jain picks his dream XI stocks for big returnsWhile we select stocks based on our algorithms in a non-discretionary manner, we can divide the team using three major types of stocks. One...
- Is this smallcap the next 'Ruchi Soya' in making? Here is what experts sayThe company is going through the process of capital restructuring through a 'scheme of arrangement' with its shareholders approved by Natio...
- Sebi probing recent rally in Ruchi Soya, Alok IndustriesSebi is investigating whether there have been instances of circular trading in the two stocks, the two people said.
- Up to 780% return in 50 days: Stocks you overlooked are making crorepatisStocks from among those that traded below Rs 10 have burst forth to deliver eye-popping gains.
- What changed your markets while you were sleepingLet’s check out what all might influence Dalal Street through the day.
- ETMarkets Evening Podcast: Trading tips from D-Street expertsListen in! Who moved your market today
- Valuations off highs but uncertainty remains in pharma sector, says Alok Dalal, CLSAPharmaceutical companies have corrected sharply from their highs but it is difficult to say that the worst is behind.
- Mapping the Market: Infosys, ICICI Bank gain more than whole market in a dayA fresh spike in oil prices outweighed concerns over the outcome of Fed’s rate-setting and drove D-St, as investors somehow digested India'...
- Faster USFDA nod won't boost margins, will lead to intense competition: AnalystsIndian drug makers may be receiving an increasing number of approvals from the USFDA for drug launches in the United States.
- Dr Reddy’s Laboratories posts muted growth in profit at Rs 2,218 crDespite a 12% growth in revenues at Rs 14,819 crore, the company ended up with a marginal growth of 3% in net profit at Rs 2,218 crore.
- Weak US sales growth hits Dr Reddy's net profitThe global generics business, which contributes 82 per cent of total revenues, grew 8 per cent at Rs 3,169 crore.
- Indian generic drug makers like Lupin, Dr Reddy’s Laboratories, Sun Pharma eye Japanese marketIn April, Lupin formed a joint venture with Japan’s Yoshindo for biosimilars. It is also in talks with other local drug makers for alliance...
- Argentina opens $6 billion industry for Indian pharmaceutical companiesWith effect from August 8, the Latin American nation has included India on the list of countries that can supply medicines to it.
- Sanofi files cases against Glenmark on patent infringementSanofi had submitted its application to seek US Food and Drug Administration's (USFDA's) approval for its generic version of the drug on Ja...
Load More
